Industry Strength Score
22/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MAXCYTE INC (MXCT) Stock Price & Overview
NASDAQ:MXCT • US57777K1060
Current stock price
0.88 USD
0 (0%)
Last:
The current stock price of MXCT is 0.88 USD. Today MXCT is down by 0%. In the past month the price increased by 17.4%. In the past year, price decreased by -68.79%.
MXCT Key Statistics
52-Week Range0.6434 - 2.86
Current MXCT stock price positioned within its 52-week range.
1-Month Range0.6748 - 0.8999
Current MXCT stock price positioned within its 1-month range.
- Market Cap
- 94.037M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.37
- Dividend Yield
- N/A
MXCT Stock Performance
Today
0%
1 Week
+1.95%
1 Month
+17.40%
3 Months
-2.96%
Longer-term
6 Months -42.86%
1 Year -68.79%
2 Years -80.36%
3 Years -78.43%
5 Years N/A
10 Years N/A
MXCT Stock Chart
MXCT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MXCT. When comparing the yearly performance of all stocks, MXCT is a bad performer in the overall market: 92.16% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MXCT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MXCT. No worries on liquidiy or solvency for MXCT as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MXCT Earnings
On March 24, 2026 MXCT reported an EPS of -0.06 and a revenue of 7.30M. The company beat EPS expectations (26.47% surprise) and missed revenue expectations (-23.91% surprise).
Next Earnings DateMay 12, 2026
Last Earnings DateMar 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.06
Revenue Reported7.3M
EPS Surprise 26.47%
Revenue Surprise -23.91%
MXCT Forecast & Estimates
13 analysts have analysed MXCT and the average price target is 4.37 USD. This implies a price increase of 396.79% is expected in the next year compared to the current price of 0.88.
For the next year, analysts expect an EPS growth of 27.83% and a revenue growth -9.3% for MXCT
Analysts
Analysts83.08
Price Target4.37 (396.59%)
EPS Next Y27.83%
Revenue Next Year-9.3%
MXCT Index Membership
MXCT is currently included in the following stock indexes tracked on ChartMill.
MXCT Financial Highlights
Over the last trailing twelve months MXCT reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 5.13% compared to the year before.
Income Statements
Revenue(TTM)33.03M
Net Income(TTM)-44.63M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.04% | ||
| ROE | -26.02% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%40%
Sales Q2Q%-16.02%
EPS 1Y (TTM)5.13%
Revenue 1Y (TTM)-14.5%
MXCT Ownership
Ownership
Inst Owners68.87%
Shares106.86M
Float100.06M
Ins Owners1.6%
Short Float %5.41%
Short Ratio5.47
MXCT Industry Overview
MXCT operates in the Life Sciences Tools & Services sub-industry within the Health Care sector. This group contains 50 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
51/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
39%
Outperformed 39% of sub-industries
3 Month Rank
8%
Outperformed 8% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 50
- New Highs
- 0%
- New Lows
- 8%
- Average ROE
- 15.1%
- Average Profit Margin
- 15.6%
- Average Operating Margin
- 18.8%
- Average P/E
- 33.7
- Average Fwd P/E
- 28.9
- Average Debt/Equity
- 0.8
MXCT Competitors/Peers
The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 17.32 | 174.368B | ||
| DHR | DANAHER CORP | 19.03 | 123.954B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 135.35 | 44.523B | ||
| A | AGILENT TECHNOLOGIES INC | 17.04 | 32.363B | ||
| WAT | WATERS CORP | 21.12 | 30.15B | ||
| IQV | IQVIA HOLDINGS INC | 12.3 | 26.485B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.98 | 25.658B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.45 | 21.673B | ||
| ILMN | ILLUMINA INC | 22.75 | 20.626B | ||
| MEDP | MEDPACE HOLDINGS INC | 21.57 | 11.925B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.867B | ||
| RVTY | REVVITY INC | 15.75 | 9.691B | ||
| TECH | BIO-TECHNE CORP | 24.77 | 8.608B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MXCT
Company Profile
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Company Info
IPO: 2016-03-29
MAXCYTE INC
9713 Key West Avenue,, Suite 400
Rockville MARYLAND US
CEO: Doug Doerfler
Employees: 114
Phone: 13015175556
MAXCYTE INC / MXCT FAQ
What does MXCT do?
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Can you provide the latest stock price for MAXCYTE INC?
The current stock price of MXCT is 0.88 USD.
What is the dividend status of MAXCYTE INC?
MXCT does not pay a dividend.
What is the ChartMill technical and fundamental rating of MXCT stock?
MXCT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about MAXCYTE INC (MXCT) stock?
13 analysts have analysed MXCT and the average price target is 4.37 USD. This implies a price increase of 396.79% is expected in the next year compared to the current price of 0.88.
How many employees does MAXCYTE INC have?
MAXCYTE INC (MXCT) currently has 114 employees.
When does MAXCYTE INC (MXCT) report earnings?
MAXCYTE INC (MXCT) will report earnings on 2026-05-12.